Taiwan's Bora Pharmaceuticals in potential $2.5 billion collaboration with Insilico Medicine (updated)

China Medical System Holdings

15/07/2026 03:22

Adding details and context
July 15 (Reuters) - Taiwan-based contract drugmaker Bora Pharmaceuticals 6472.TW will partner with Insilico Medicine 3696.HK on a collaboration aimed at improving efficiency, potentially valued at more than $2.5 billion if fully implemented, the drug discovery firm said on Wednesday. 
Collaboration to "explore opportunities" for automation in areas including pharmaceutical development, process optimisation and quality systems, Insilico said in a statement.
Collaboration expected to apply Insilico capabilities to improve efficiency in manufacturing, supply chain, distribution and corporate operations.
"Together, we aim to build a scalable and repeatable model that can advance promising drug candidates more efficiently, positioning Bora at the forefront of AI-enabled pharmaceutical development and manufacturing, and establish a long-term growth platform through the development and commercialisation of high-value proprietary assets," Bora CEO Bobby Sheng said in a statement. 
Insilico has previously announced partnerships with Asia-based drugmakers including China Medical System 0867.HK and Japan's Takeda Pharmaceutical 4502.T. 

 (Reporting by Andrew Silver in Shanghai; Editing by Jacqueline Wong)
 ((andrew.silver@thomsonreuters.com))